BIIB

#489
Biogen Inc. Common Stock
180.68 USD
+2.44%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
177.45
180.85
1年のレンジ
114.66
202.41
1日の変化
+2.44%
月次変化
-1.14%
6か月変化
+24.83%
1年の変化
+51.88%
以前の終値
176.37
始値
177.71
Bid
Ask
安値
177.45
High
180.85
ボリューム
150
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 26.52 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
20.02
売上高対価格比率
2.62

Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

ニュース